The last update said if biotech SPBIO, made a new daily high, the bulls would be gaining a foothold.
That new high and the foothold, have come and gone.
Admittedly, the retrace in SPBIO and inverse LABD went farther than anticipated.
However, as of this morning’s action, the attempt to move higher in biotech has either failed outright, or has been severely damaged.
If it’s failure, then we’re set up for a major downside move.
The daily chart of inverse LABD, has the now familiar trend-lines that are a repeating pattern.
The last two days may have formed yet another right side trend; rising at the same angle as the others on the chart.
There’s a remote chance, as price action nears SPBIO support (LABD near 30), the bulls could once again attempt to reverse course.
With the overall market oscillating to the downside (today’s counter move notwithstanding) and with biotech in the downside lead, an upside move seems unlikely.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Massive downside potential for biotech SPBIO; upside for inverse, LABD.
Unless there’s some kind of unexpected reversal, LABD is showing its colors … huge upside potential.
As expected, LABD has completed its testing action previously discussed in these two updates; here and here.
At the minimum, we’ve got a right side LABD trend that if followed, will result in a doubling of current price near the end of this month or early next.
A trailing stop can be used which adheres to the (now confirmed) trend; not advice, not a recommendation.
If LABD really is in the channel shown, the top of the range even at this point, is around the 170-level; nearly 550%, from current price.
As always, anything can happen. For now, we’re sitting tight and letting price action dictate the next trading move.
The Project Stimulus account will need to get above the $2,000 level before margin is allowed (by the broker).
By that time, it may be a moot point; volatility could be too high for any kind of size increase.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
It’s possible, after ‘Day 55’, LABD (above) attempted to negate the uptrend (pushing out of the right side) … only to find itself a few days later back in the channel.
Looking at the big picture, could or will LABD reach the upper channel line?
Is that possible?
After the experience with oil futures going negative (last year) the first time in market history, it should be obvious, anything can happen.
If LABD’s in the trading channel shown, we’re still in the early stages of the move.
Today, the expectation is for price action to reverse; coming back to close (or test) near the trend line around 23.90 – 24.30.
If it does and then gaps higher tomorrow (Friday), thus confirming the trend, it’s potentially the last stop for low risk positioning (not advice, not a recommendation).
Otherwise, with LABD up 7%, as of this post, we could already be off to the races.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: The last two links do not verify the veracity of the referenced material. Be advised.
Momentum is building for some kind of ‘tipping point’.
We may be there now.
We’re looking for an avalanche of reports whose combined (fundamental and technical) effect is catastrophic implosion of the biotech sector.
Market Analysis:
The chart speaks for itself. It’s obvious biotech has reversed and could be in serious trouble.
The inverse fund LABD is up a stiff 10.5%, as of this post:
We may or may not have a trading channel as shown.
The right side trendline will need more confirmation. As always, anything can happen and the nascent move could fall apart.
However, what is known:
SPBIO’s (and LABD’s) pivot was called ‘to the day’.
The “Iceberg” notation references this report, where the probability of SPBIO downside at that juncture was presented.
That analysis was correct. SPBIO never looked back.
Positioning:
Our ‘project’ position remains open (not advice, not a recommendation). The correct stance under current circumstances is to let price action take LABD higher.
As Livermore said nearly a century ago, the hard part now is to ‘sit tight’. Let the market determine when the move has ended.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Time and technical have come together; indicating potential downside collapse in biotech.
Collapse potential is immense and has been for years.
Fibonacci 55 days after the 2/10/21, highs, biotech (SPBIO), pivots decisively lower.
Of all the major indices, biotech on a percentage basis, is the downside leader.
Rightly so.
Fundamentally, it’s poised to disintegrate with its illegal, Mengele style campaign of medical experimentation.
Who knows if that full disclosure will happen.
The ‘controllers’, the oligarchs, may come up with some other mechanism to usurp the media, the internet and keep it all under wraps.
However, it looks like the tide’s turning.
Remember, the market leads the news; not the other way around.
If biotech goes into its well deserved collapse, downside action itself will be the catalyst for exposure.
For now, SPBIO is pivoting lower; LABD higher.
The daily chart of LABD shows the Fibonacci time relationship. From low to low; Fibonacci 55 days.
Yesterday, the 28th, was Day 55.
Today, LABD has already posted a new daily high … weighting probability to more upside (SPBIO, lower).
The next chart has the potential trading channel.
It looks aggressive.
However, the market itself has defined the trend.
Shown, in pervious updates, this trend angle has been repeated at least four times from March 5th, LABD high, to yesterday’s low.
It’s no guarantee. We’ll let subsequent price action confirm or negate the right side trend.
As of this post, LABD continues to push aggressively higher.
Our ‘project’ has an open position in LABD.
Without revealing specifics of that position (discussed previously), it’s represented in the table below:
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Inverse fund LABD breaks out from a wedge pattern (to the downside) on reduced thrust energy.
Has this downside (upside for biotech SPBIO) reached exhaustion?
The 2-Hour chart above shows drastically reduced thrust (volume-price) energy to the downside. In addition, a wedge is typically the last formation at the end of a move.
Price action is the final arbiter. We won’t know if SPBIO will resume its downtrend (LABD higher) until there’s a definitive reversal.
Early action stopped out the ‘project’ position with a small profit as shown in the table:
We’re going to make changes on how the trades in the project are shown; more on that later.
Fundamentals:
The speck injection horror show continues with this 1-hour, 20-minute meeting of internationally acclaimed medical physicians.
You’ll never seem them on the mainstream.
The bottom line is those who have received the speck protection are a threat to the well-being of everyone else.
Some of the physicals have discussed potential action such as quarantine (or visual identification) of those who have received this so-called protection.
That’s right, it’s the people who have subjected themselves to the gene altering therapy that are now the potential threat.
Possible remedial actions are discussed. The video is a must see.
Stay Tuned
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
All of the above provides the backdrop for biotech.
It’s interesting (then again, not really) how this sector’s nascent bear market’s being ignored by the financial press.
Instead of a breakout to the downside (as expected), yesterday the sector SPBIO, decided to test the 23.6%, retrace area.
Today’s early session was spent testing (to the upside) the resistance area.
Price action is now tentatively reversing; about to head lower again.
The hourly chart of LABD (3X inverse SPBIO) shows yesterday’s exit (well past the stop) and re-entry of the short position; not advice, not a recommendation.
For reasons that may be covered later, the stop was not in the market at the time.
In addition, there was a trading platform lock-up (on the broker’s side) at exit and re-entry. A series of amateur-like errors all around.
It’s just a reminder to all; when the market turns lower in earnest, brokers and their trade platforms may (probably will) become inoperative.
The whole event resulted in a significant ding to our ‘project account’
How quickly can this recover … we’ll see.
Below, we have the hourly chart again … but noted with what looks like a nascent trend.
That trend line was copied and re-positioned over prior LABD moves.
Note how this market repeats its characteristics. This angle of trend line has happened three times in the past month.
We’re back in position. The chart has been updated and the stop (now in the market, GTC) listed at 20.96 (above break-even):
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
4:36 p.m. EST: Updated with additional data below in red
10:26 a.m. EST:
If the adverse event database can be trusted (a question in itself), the number of people recently injected with ‘speck’ protection, has fallen off a cliff.
The April 16th update linked here, had this to say:
“You would think it’s just a matter of time before this reaches some kind of tipping point; where enough of the herd realizes all at once, the lie.”
The abrupt halt in reaction uploads would indicate a jump in collective awareness the ‘speck’ is a lie … just in time for the next ‘event’ (likely to be food supply or cyber disruption).
Before we get to any market analysis, there’s one more thing concerning biotech … the masks.
Since investigative reporting has been usurped by controlling entities pushing false narratives, information now has to come from the individual(s).
That data is typically in raw form; unlike the slick presentations (i.e. lies) we’ve grown used to on the mainstream.
It’s now up to the researcher to do the leg-work on what’s real or not.
However, this link, appears to be above-board. Download the file if your viewer will not work.
A medical professional has investigated (internet rumored) mask contamination and has found disturbing results.
She is visibly shaken by her findings … probably realizing for the first time, the level of evil that’s directing controlling interests, world events.
She can’t fathom that someone would intentionally put parasites in a product that’s being pushed by the mainstream for us (and children) to wear ‘two … or three’.
Unfortunately, that’s where we are.
This author knows for a fact, a certain big-box home improvement store, handed out boxes of these same (type of) masks ‘for free’ to its employees.
When those employees for the most part, refused to wear them …. it then became a corporate directive, subject to termination.
Most of those employees eventually replaced the paper with a nylon-based covering. However, looking at the video, it seems like just one exposure to the paper masks is enough to inflict unknown levels of harm.
Intentional parasitic contamination … one more brick, in biotech.
You’ll have to make your own call. Both sides (parasites non parasite) are presented in this update.
Since the author of these posts has never worn a toilet-paper mask (or any mask), what’s on them does not apply from a personal standpoint.
Nonetheless, many in the public can be seen using this type of so-called protection.
Either way, the technical condition of biotech remains …
Moving on to the markets:
The chart of LABD (3X Inverse SPBIO), continues to move higher.
Our project position is being maintained (see table) and the stop has been moved up as shown:
Obviously, there’s a lot going on in the markets and elsewhere. There’s no telling when or if it will all break loose.
No matter; If that happens, we’re positioned (not advice, not a recommendation) in a market that’s already moving lower … pushing LABD higher.
Stay Tuned
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
You have to wonder; once the ruling oligarchs are finished with the first (‘speck’) round, moving on to the next fabricated crisis, if biotech’s not going to be thrown under the bus.
After all, its served its purpose.
According to comments posted beneath this article, about 33%, of the U.S. population have (apparently, voluntarily) injected themselves.
According to this link, it’s about 24%, of the population.
Either way, it’s a lot … in the tens of millions.
It’s a crazy business model; systematically destroy your customer base.
Said many times in these updates, attempting to match fundamentals to technicals is usually not successful.
Sector Analysis:
Referring back to Ed Seykota, in his ‘Market Wizards‘ interview, he said using fundamentals as a basis for positioning, rarely if ever, worked.
Still, it’s undeniable something very wrong is going on in the sector.
Our market table has been updated and we’ve included the S&P Biotech Sector, SPBIO:
All markets are within fractions of a percent of all time highs except for semis, mid-caps and biotech.
The S&P biotech is down a whopping, 25%.
It’s already well in bear market territory.
Positioning:
Since we’re working the short side (not advice, not a recommendation), the focus is on biotech and specifically LABD.
The fund attempts to track the 3X inverse of SPBIO.
With that kind of leverage, LABD has significant downside bias. Positioning (from experience) is best suited when the move is sustainable and persistent.
Looking at the chart of LABD, we could be there. At this time, the fund is trending higher at a stiff +820%, on an annualized basis.
Project Stimulus:
Our Project account is positioned as shown. Since the account’s not large enough to enable leverage as determined by the broker, we just have to wait it out till it gets there (currently set at $2,000).
Summary:
Stated in The Rich And The Super Rich (if memory serves), not since Marie Antionette have the ruling oligarchs allowed themselves to be out in the open.
Seems like her demise cured them of having to get (direct) attention.
That would mean, people in the public eye at this point, are just useful idiots. And when their usefulness has run its course … ???
From watching them, it’s obvious they’re delusional … thinking they can tame evil (even harming children) and escape wrath.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
The Danger Point® 